@article{oai:kanazawa-u.repo.nii.ac.jp:00013857,
 author = {Kita, Yuki and Takamura, Toshinari and Misu, Hirofumi and Ota, Tsuguhito and Kurita, Seiichiro and Takeshita, Yumie and Uno, Masafumi and Matsuzawa-Nagata, Naoto and Kato, Ken-ichiro and Ando, Hitoshi and Fujimura, Akio and Hayashi, Koji and Kimura, Toru and Ni, Yinhua and Otoda, Toshiki and Miyamoto, Ken-ichi and Zen, Yoh and Nakanuma, Yasuni and Kaneko, Shuichi},
 issue = {9},
 journal = {PLoS ONE},
 month = {Sep},
 note = {Background: Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Methodology/Principal Findings: Eight-week-old C57BL/6 mice were fed a methionine- and choline-deficient plus high fat (MCD+HF) diet with or without 0.1% metformin for 8 weeks. Co-administration of metformin significantly decreased fasting plasma glucose levels, but did not affect glucose tolerance or peripheral insulin sensitivity. Metformin ameliorated MCD+HF diet-induced hepatic steatosis, inflammation, and fibrosis. Furthermore, metformin significantly reversed hepatic steatosis and inflammation when administered after the development of experimental NASH. Conclusions/Significance: These histological changes were accompanied by reduced hepatic triglyceride content, suppressed hepatic stellate cell activation, and the downregulation of genes involved in fatty acid metabolism, inflammation, and fibrogenesis. Metformin prevented and reversed steatosis and inflammation of NASH in an experimental non-diabetic model without affecting peripheral insulin resistance. © 2012 Kita et al.},
 title = {Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis},
 volume = {7},
 year = {2012}
}